TinyGemsBreaks Archive

FridayMar 20, 2026 9:40 am

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Signs Strategic Cooperation Agreement With BonV Aero To Expand Counter-UAS Presence In India

ParaZero Technologies (NASDAQ: PRZO) announced the signing of a strategic cooperation agreement with India-based BonV Aero to market its portfolio of counter-UAS solutions, led by the DefendAir system, a mobile, net-based interception platform designed for rapid deployment against hostile drones, while also enabling future configurations and integrations. The companies have already conducted a live demonstration of the portable DefendAir launcher for a key security entity in India, validating its real-world effectiveness and positioning ParaZero to expand its presence in a strategically important market as it explores additional collaboration opportunities across counter-drone applications. To view the full press release, visit https://ibn.fm/maAxq…

TuesdayMar 17, 2026 10:30 am

TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update

Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2025, alongside a shareholder update highlighting operational, clinical and financial progress. The company reported key 2025 milestones including restored NYSE American compliance, a $16.5 million capital raise, U.S.-based drug manufacturing transition and advancement of its ONP-002 program, while outlining early 2026 progress toward Phase IIa trial initiation in Australia and strategic priorities focused on patient enrollment, U.S. regulatory advancement and expansion of its CNS pipeline. To view the full press release, visit https://ibn.fm/Dg7JA About Oragenics, Inc. Oragenics, Inc. is a…

MondayMar 16, 2026 9:25 am

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Completes MainLine System Proof of Concept In India

Rail Vision (NASDAQ: RVSN) announced the successful completion of a proof of concept demonstration of its AI-integrated MainLine railway safety system in India following a two-month evaluation conducted under real-world operating conditions with a major local rail operator in collaboration with Sujan Industries. The company said the trial assessed real-time object detection and classification, operational stability and performance across varying environmental conditions, with the customer providing positive feedback and indicating the system is suitable for further evaluation and potential controlled deployment across the Indian railway network. To view the full press release, visit https://ibn.fm/22W4I About Rail Vision Ltd. Rail Vision…

FridayMar 13, 2026 9:50 am

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Receives Counter-UAS Order from Israeli Defense Entity

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company developing autonomous solutions for the global manned and unmanned aerial systems industry, announced it has received a new purchase order from an Israeli defense entity for its DefendAir counter-unmanned aerial systems platform. The order includes delivery of an evaluation kit featuring DefendAir net pods along with live exercises and training intended to support rapid operational deployment and readiness. The DefendAir system uses patented non-explosive net-launcher technology designed to neutralize hostile drones while minimizing collateral impact and addressing evolving aerial threats across urban and battlefield environments. To view the full press release, visit…

WednesdayMar 11, 2026 9:30 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated mechanisms, clear development pathways and strong commercial potential, while preparing legacy assets TPI 287 and berubicin for potential out-licensing to focus resources on advancing a new acquisition-driven pipeline. To view the full press release, visit https://ibn.fm/MutVR About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage…

TuesdayMar 10, 2026 9:20 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents TONMYA Data at International Fibromyalgia Congress

Tonix Pharmaceuticals (NASDAQ: TNXP) announced two oral presentations on TONMYA(TM), investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. Post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies highlighted rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia, including statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15…

FridayMar 06, 2026 3:13 pm

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move. “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors,” said Professor Steve Myers, the former Director of Accelerators and Technology…

FridayMar 06, 2026 9:12 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(TM). Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA’s proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism. The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to…

TuesdayMar 03, 2026 10:10 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Approved to Transfer Listing to Nasdaq Global Select Market

Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher tier expected to begin at the open of market on March 3, 2026, under the existing ticker symbol “TNXP.” The move reflects the company’s compliance with the Nasdaq Global Select Market’s more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on…

MondayMar 02, 2026 9:45 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks